




Ministerie van Volksgezondheid,
Welzijn en Sport

The Netherlands

Ministry of Health, Welfare and Sport

Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector



OUT - PATIENT IN - PATIENT

Ministry of Health Welfare and Sport is the **competent authority** for pricing and reimbursement. The Health Care Institute assesses the NCE's but the Minister takes the decision for approval. Everyone who lives or works in the Netherlands is obliged to have a basic insurance and is a payer.

Hospitals and the health insurers (in accordance with the national basic health insurance package) are the **competent authorities** for pricing and reimbursement in the in-patient/hospital sector. Everyone who lives or works in the Netherlands is obliged to have a basic insurance and is a payer.

Pricing in the out-patient sector

Pricing policies for medicines

Internal Reference Pricing
External Reference Pricing
Preference Policy (generic substitution)

Pharmacy remuneration

Prescription remuneration

VAT

9%

Reforms

Change in ERP basket (Germany out and Norway in (2020))

Pricing in the in-patient/hospital sector

Pricing policies for medicines

The insurer and the hospital sign a contract on the basis of **DRG's**. Due to competitive contracting between hospitals and insurers most prices are confidential except list prices.

Add-on (high cost medicines): If a medicine costs € 1000,- or more, a reimbursement of the actual list price can be requested by the hospital.

Price negotiations on national level.

VAT

9%

HTA process: outpatient drugs: positive list: market authorization -> HTA -> reimbursement decision by Minister -> reimbursement

Inpatient: direct reimbursement -> HTA if annual budget exceeds 10 millions

OUT - PATIENT IN - PATIENT

Medicines are not covered by public funds

Coverage / reimbursement in the out-patient sector


Positive / negative list

Yes

Reference price system (RPS) of cluster of substitutable medicines:

Yes, since 1991

Request after registration (EMA or CBG) of the manufacturer



Co-payment

Product co-payment: if a price of a product is higher than the reimbursement limit.

Co-payment out-patient medicines in 2018 € 43 million (€ 14 million has not been refunded because of a repayment arrangement of the manufacturers).

The patient's out-of-pocket payments on medicines is maximized at € 250,00 per patient per year

Reforms

Revision of the Internal Reference Pricing System. We haven't decided yet what we are going to do but it has to be finished in 2022

Coverage / reimbursement in the in-patient sector

Reimbursement of medicines

According to the Health Insurance Law

Hospital formularies

no

Co-payment in hospitals

no

No reforms